Synthesis and biologic evaluation of a novel 18F-labeled adnectin as a PET radioligand for imaging PD-L1 expression
…, P Morin, D Lipovšek, J Gokemeijer… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The programmed death protein (PD-1) and its ligand (PD-L1) play critical roles in a checkpoint
pathway cancer cells exploit to evade the immune system. A same-day PET imaging …
pathway cancer cells exploit to evade the immune system. A same-day PET imaging …
[HTML][HTML] T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation–updated consensus and review 2020
V Jawa, F Terry, J Gokemeijer, S Mitra-Kaushik… - Frontiers in …, 2020 - frontiersin.org
Immune responses to protein and peptide drugs can alter or reduce their efficacy and may
be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical …
be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical …
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin
…, AC Mita, K Sankhala, E Furfine, J Gokemeijer… - Clinical Cancer …, 2011 - AACR
Purpose: To determine the maximum tolerated dose (MTD), safety, pharmacokinetics,
pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), …
pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), …
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2
…, J Abramowitz, S Aslanian, AC Lim, J Gokemeijer… - MAbs, 2010 - Taylor & Francis
CT-322 is a new anti-angiogenic therapeutic agent based on an engineered variant of the
tenth type III domain of human fibronectin, ie, an AdnectinTM, designed to inhibit vascular …
tenth type III domain of human fibronectin, ie, an AdnectinTM, designed to inhibit vascular …
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
…, J Hosbach, J Brown, E Fitzpatrick, J Gokemeijer… - MAbs, 2011 - Taylor & Francis
Engineered domains of human fibronectin (Adnectins™) were used to generate a bispecific
Adnectin targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor-I …
Adnectin targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor-I …
[PDF][PDF] Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro
EV Getmanova, Y Chen, L Bloom, J Gokemeijer… - Chemistry & biology, 2006 - cell.com
Using directed in vitro protein evolution, we generated proteins that bound and antagonized
the function of vascular endothelial growth factor receptor 2 (VEGFR2). Binders to human …
the function of vascular endothelial growth factor receptor 2 (VEGFR2). Binders to human …
Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in …
…, R Meier, X Guan, P Phillips, G Bajaj, J Gokemeijer… - 2017 - ascopubs.org
104 Background: BMS-986156 is a fully human IgG1 agonist mAb that binds GITR and
promotes T effector cell activation and possible reduction/inactivation of T regulatory cells. …
promotes T effector cell activation and possible reduction/inactivation of T regulatory cells. …
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence …
SJ Wang, ST Wu, J Gokemeijer, A Fura… - Analytical and …, 2012 - Springer
High-performance liquid chromatography–tandem mass spectrometry (LC-MS/MS) and
enzyme-linked immunosorbent assay (ELISA) methods were developed for the quantification of …
enzyme-linked immunosorbent assay (ELISA) methods were developed for the quantification of …
How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective
J Gokemeijer, V Jawa, S Mitra-Kaushik - The AAPS Journal, 2017 - Springer
In silico HLA-binding algorithms and in vitro T cell-based assays as predictive tools for
human immunogenicity risk have made inroads in the biotherapeutic drug discovery and …
human immunogenicity risk have made inroads in the biotherapeutic drug discovery and …
An IQ consortium perspective on best practices for bioanalytical and immunogenicity assessment aspects of CAR‐T and TCR‐T cellular therapies development
J Gokemeijer, N Balasubramanian… - Clinical …, 2024 - Wiley Online Library
CAR‐T therapies have shown remarkable efficacy against hematological malignancies in
the clinic over the last decade and new studies indicate that progress is being made to use …
the clinic over the last decade and new studies indicate that progress is being made to use …